Delivery Order SPE2DB25D3018-SPE2DB25FUYGP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a completion date of July 31, 2025. This firm fixed-price delivery order, issued on July 30, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,391.32 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,625.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 120 mL quantities, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed-price contract was competitively awarded on July 28, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a transaction under the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,363.38. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The contract involved no set-aside designation and was...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYGPDelivery Order
The Defense Logistics Agency awarded a $4,515.00 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. This is a firm fixed-price delivery order with a completion date of August 19, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Quillivant XR is a common pharmaceutical product used primarily for attention-deficit/hyperactivity disorder treatment, consistent with AmerisourceBergen's role as a critical pharmaceutical distributor to federal military and veteran healthcare systems. As a major pharmaceutical wholesaler, AmerisourceBergen regularly fulfills diverse medical supply requirements across multiple therapeutic categories through its prime contract vehicle with the Defense Logistics Agency. The company's comprehensive federal contract portfolio demonstrates its capability to meet competitive procurement standards and support the Defense Health Agency and other government healthcare systems with both routine pharmaceutical replenishments and specialized medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 8/18/25 |